What Matica Biotechnology does

Matica Biotechnology is a viral vector and gene therapy Contract Development and Manufacturing Organization (CDMO) headquartered in College Station, Texas, founded in 2019 and operating as a U.S. subsidiary of South Korean conglomerate CHA Biotech. The company provides end-to-end CDMO services spanning cell line and vector development, upstream and downstream process development, assay development, GMP production, and quality services for advanced therapy developers, academic medical centers, and pharmaceutical companies. Its proprietary technology stack centers on the MatiMax™ cell line platform, in-line process monitoring, and single-use manufacturing systems, delivered from a purpose-built cGMP facility and supported by a network of five Matica sites worldwide.

The company's commercial model is fee-for-service / professional services, with project-based contracts for GMP manufacturing, process and analytical development, and regulatory support (IND and BLA filings). It has disclosed >300 viral vector projects, >36 cell therapy projects, >20 IND filings prepared, and 5 BLA project filings managed. In June 2026, Matica launched two new platform offerings: the Open Access Platform for AAV, which provides flexible, non-exclusive manufacturing pathways with retained client IP (anchored by Cirsium Biosciences), and the Korea IIT Integrated Platform, which combines Korean clinical trial infrastructure with U.S.-based manufacturing for investigator-initiated trials. The company is led by CEO Paul H. Kim (appointed October 2024, 30+ years of CDMO/CRO/biotech experience) and CCO Min Park (25+ years, formerly CBO at WuXi Advanced Therapies, Catalent, Samsung Biologics, Abzena, and DSM), with technical leadership drawn from Genentech, Amgen, Fujifilm Diosynth, and Boehringer-Ingelheim.

Name

Matica Biotechnology

Legal name

Matica Biotechnology, Inc.

Website

https://maticabio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Matica Biotechnology is a viral vector and gene therapy CDMO providing end-to-end cGMP manufacturing, process development, and analytical services to biotech, pharma, and academic developers from its purpose-built Texas facility and five global sites.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing (Viral Vector CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Cell Therapy CDMO (HLAGABAD)

Keywords

• Viral vector manufacturing
• Gene therapy CDMO
• Cell therapy development
• Contract manufacturing services
• GMP production services

Headquarters

HQ city

College Station

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Contract Manufacturing Services: Matica Bio provides fee-for-service CDMO manufacturing services including cell line development, process development, assay development, GMP production, and quality services. Revenue is generated through project-based contracts with biotech and pharma clients for viral vector manufacturing across clinical and commercial stages.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Matica Biotechnology is a viral vector and gene therapy Contract Development and Manufacturing Organization (CDMO) providing end-to-end manufacturing services from cell line and process development through cGMP production and quality release. Its offering is delivered at a purpose-built cGMP facility in College Station, Texas, leveraging proprietary MatiMax™ cell lines, in-line process monitoring, and single-use technologies, and is extended globally through an integrated Korea–U.S. platform.

Product overview

Matica Biotechnology is a viral vector Contract Development and Manufacturing Organization (CDMO) offering a comprehensive suite of advanced therapy manufacturing services. The company's portfolio includes the MatiMax™ proprietary cell line platform for enhanced production, the Open Access Platform for AAV providing flexible non-exclusive manufacturing pathways, and an integrated Korea IIT Platform Solution combining Korean clinical trial infrastructure with U.S. manufacturing. Core services span cell line and vector development, process development, assay development, GMP production, and quality services—all delivered through purpose-built cGMP facilities utilizing advanced technologies, in-line process monitoring, and single-use systems across five Matica sites worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• MatiMax™ Platform: Proprietary cell line platform for advanced therapy manufacturing
• Open Access Platform
• Accelerated Matica Korea IIT Integrated Platform Solution

Products and services

• MatiMax™ Platform Proprietary cell line platform developed by Matica Biotechnology for enhanced viral vector and gene therapy manufacturing, representing the company's core proprietary technology for cell-based production.
• Open Access Platform for AAV Open-access manufacturing platform providing flexible, non-exclusive AAV manufacturing pathways with transparent process development, data access, and accelerated scalability from early development to commercial readiness, designed for gene therapy innovators.
• Cell and Gene Therapy Development and Manufacturing Services End-to-end solution for advanced therapy manufacturing spanning the entire product lifecycle from development through commercialization, integrating clinical execution with GMP manufacturing, process development, analytical development, and regulatory support for biotech, pharma, and academic clients.
• Cell Line and Vector Development Development and production of cell lines and viral vectors for gene therapy applications, including proprietary MatiMax™ cell lines and various viral vector platforms, provided to biotech, pharma, and academic clients.
• Process Development Upstream and downstream process development services for viral vector manufacturing, including upstream process development, downstream process development, and process engineering delivered to advanced therapy developers.
• Assay Development Analytical method development and validation services for characterizing viral vectors, including methods for wild-type and recombinant viruses across all biosafety levels (BSL1–BSL4), provided to gene therapy and cell therapy developers.
• GMP Production cGMP manufacturing services for viral vectors and gene therapies performed at the company's purpose-built cGMP facility in College Station, Texas, utilizing advanced technologies and single-use systems for advanced therapy clients.
• Quality Services Quality control testing and quality services supporting process development, GMP manufacturing, and product release for advanced therapy manufacturing, serving gene therapy and cell therapy clients.
• Korea IIT Integrated Platform Solution Integrated platform solution combining Korean clinical trial infrastructure with U.S.-based manufacturing capabilities, designed to accelerate investigator-initiated trials (IITs) and early translational development for global cell and gene therapy programs.

Quantifiable outcome

• >20 IND filings prepared for clients
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered core and minor.

• Cirsium BiosciencescoreStrategic or Co-development Partner · 16 June 2026Matica Bio and Cirsium Biosciences announced adoption of the Matica Open Access Platform for AAV manufacturing. The partnership integrates Cirsium's plant-based AAV technology with Matica Bio's downstream and analytical expertise, providing flexible, transparent, and scalable gene therapy manufacturing under an open-access model.
• University Health Network (UHN)coreStrategic or Co-development Partner · 9 June 2026Matica Bio engaged by UHN's Toronto General Hospital to supply cGMP manufacturing of IL-10 adenoviral gene therapy designed for delivery to donor lungs during ex vivo lung perfusion prior to transplantation. Services include research cell bank generation, adenovirus seed synthesis, process development, analytical development, testing, and cGMP manufacturing.
• Major North American Research InstitutioncoreStrategic or Co-development Partner · 26 March 2026Matica Bio signed a CDMO contract with a major North American research institution for adenovirus therapeutics development covering stages from process development to cGMP manufacturing.
• Calidi BiotherapeuticscoreStrategic or Co-development Partner · 3 November 2025Strategic partnership to support IND submission for Calidi's oncolytic virus therapy CLD-401 targeting metastatic tumors. Matica Bio provides analytical, process development, and GMP manufacturing services at its Texas facility for Calidi's cancer immunotherapy program.
• CytoImmune TherapeuticscoreStrategic or Co-development Partner · 10 October 2024Strategic partnership for viral vector and cell therapy production, combining Matica Bio's viral vector manufacturing capabilities with CytoImmune's cell therapy development expertise.
• KaliVir ImmunotherapeuticsminorStrategic or Co-development PartnerCDMO partnership for viral vector development and manufacturing services supporting KaliVir's immunotherapy programs.
• Mongoose BiominorStrategic or Co-development PartnerStrategic partnership to accelerate TCR-T cell therapy development, combining manufacturing and development expertise.
• TreovirminorStrategic or Co-development PartnerStrategic partnership to advance innovative therapies for pediatric brain tumors through manufacturing collaboration.
• Child's Cure Genetic ResearchminorStrategic or Co-development PartnerCollaboration to drive innovation in pediatric rare disease therapies through manufacturing support.
• Texas A&M National Cell Therapy Institute (NCTM)coreStrategic or Co-development PartnerStrategic partnership to deliver end-to-end support for cell and gene therapy innovators, combining Texas A&M's research capabilities with Matica Bio's manufacturing expertise.
• SartoriuscoreTechnology or IntegrationJoint research agreement for the development of advanced viral vector manufacturing technology, combining process development expertise.
• Avance ClinicalminorChannel Partner/ Reseller/ DistributorPartnership with Australian CRO Avance Clinical to provide clinical trial initiation services for Calidi Biotherapeutics programs.
• CHA Biotech (Parent Company)coreOthersMatica Biotechnology is the U.S. subsidiary of CHA Biotech, part of CHA Medical & Bio Group. CHA Biotech provides strategic support and access to the broader CHA network including Korea-based clinical infrastructure.
• SCAI TherapeuticsminorOthersPaul Kim, CEO of Matica Bio, serves on the board of SCAI Therapeutics.
• Riva TherapeuticsminorOthersPaul Kim, CEO of Matica Bio, serves on the board of Riva Therapeutics in San Diego.

Scale indicators6 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Forge Biologics: Gene therapy-focused CDMO offering AAV manufacturing, process development, and related services. Directly comparable in target market (gene therapy developers), service scope, and growth stage.
• Yposkesi: European viral vector and gene therapy CDMO offering AAV and lentiviral manufacturing for clinical and commercial stages. Direct competitor in the specialty gene therapy CDMO segment.
• Andelyn Biosciences: Specialty viral vector CDMO focused on AAV and other gene therapy vectors for clinical and commercial supply. Closest comparable peer to Matica in terms of scale, service offering, and target customer base.
• VGXI (Genezen): Viral vector CDMO providing plasmid DNA, AAV, lentivirus, and other gene therapy manufacturing services. Closely comparable specialty CDMO competing for similar gene therapy development clients.

Regional players

• Samsung Biologics: South Korea-based large-scale CDMO that is also relevant as an Asian regional peer given CHA Biotech's Korean roots. Min Park previously served as CBO at Samsung Biologics, indicating direct experience with this competitor.

Broad incumbents

• Catalent: Large-scale global CDMO with significant viral vector and gene therapy manufacturing capabilities (e.g., Paragon Bioservices acquisition). Matica's CCO Min Park previously served as CBO at Catalent, indicating direct personnel and competitive overlap.
• Lonza: One of the largest global CDMOs with established viral vector and cell therapy manufacturing capacity. Competes for similar gene therapy development and manufacturing contracts across clinical and commercial stages.
• Fujifilm Diosynth Biotechnologies: Major CDMO with viral vector and gene therapy manufacturing offerings. Multiple Matica senior leaders (Milton Pollard, Daniel Mitchell, Trent Lyman, Sarah Link) came from Fujifilm Diosynth, reflecting deep technical and competitive overlap.
• WuXi AppTec (WuXi Advanced Therapies): Global CDMO with dedicated gene and cell therapy manufacturing capabilities through WuXi Advanced Therapies unit. Min Park previously served as CBO there. Comparable full-spectrum gene therapy CDMO offering.

Others

• Sartorius: Bioprocessing equipment and integrated solutions provider with a strategic joint research agreement with Matica for advanced viral vector manufacturing technology. Comparable as an ecosystem/technology partner rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/matica-biotechnology-inc

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Matica Biotechnology